natgillin/translations-raw huggingface dataset:
The onset of pulmonary signs such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of Adult Respiratory Distress Syndrome (ARDS).
Pojav pljučnih znakov kot so kašelj, zvišana telesna temperatura in dispneja v povezavi z radiološkimi znaki pljučnih infiltratov in poslabšanje pljučne funkcije utegnejo biti preliminarni znaki sindroma dihalne stiske pri odraslih (ARDS – 'Adult Respiratory Distress Syndrome’).
The onset of pulmonary signs such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of Adult Respiratory Distress Syndrome (ARDS).
Začetek pojavljanja pljučnih znakov, kot so na primer kašelj, zvišana telesna temperatura in dispneja ob hkratnih radioloških znakih pljučnih infiltratov in ob slabšanju delovanja pljuč, lahko pomeni začetek sindroma dihalne stiske pri odraslem (ARDS - Adult Respiratory Distress Syndrome).
The onset of pulmonary signs, such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of acute respiratory distress syndrome (ARDS).
Pojav pljučnih znakov, kot so kašelj, zvišana telesna temperatura in dispneja v povezavi z radiološkimi znaki pljučnih infiltratov in poslabševanjem pljučne funkcije, so lahko predhodni znaki sindroma akutne dihalne stiske (»acute respiratory distress syndrome« - ARDS).
The onset of pulmonary signs, such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of Acute Respiratory Distress Syndrome (ARDS).
Začetek pojavljanja pljučnih znakov, kot na primer kašlja, zvišane telesne temperature in dispneje ob hkratnih radioloških znakih pljučnih infiltratov in ob slabšanju delovanja pljuč, lahko pomeni začetek sindroma akutne dihalne stiske (ARDS - Acute Respiratory Distress Syndrome).
The onset of pulmonary symptoms such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function together with an increased neutrophil count may be preliminary signs of Acute Respiratory Distress Syndrome (ARDS) (see section 4.8).
Pojav pljučnih simptomov kot so kašelj, zvišana telesna temperatura in dispneja v povezavi z radiološkimi znaki pljučnih infiltratov in poslabšanjem delovanja pljuč skupaj z zvišanjem števila nevtrofilcev so lahko predhodni znaki sindroma akutne dihalne stiske pri odraslih (Acute Respiratory Distress Syndrome - ARDS) (glejte poglavje 4.8).
The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence (≤ 4 contractions/hour) for 12 hours.
Sprostitev maternice se po atosibanu pojavi hitro in kontrakcije se v 10 minutah pomembno zmanjšajo, tako da je dosežena stabilna umiritev maternice (≤ 4 kontrakcije/uro) za 12 ur.
The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence ( 4 contractions/hour) for 12 hours.
Sprostitev maternice se po atosibanu pojavi hitro in kontrakcije se v 10 minutah pomembno zmanjšajo, tako da je dosežena stabilna umiritev maternice ( 4 kontrakcije/uro) za 12 ur.
The OPA GMTs were similar or higher following a single dose than a 3 dose primary course in infants below 6 months of age, except for serotype 5.
GMT OPA so bile po enkratnem odmerku podobne ali višje kot po primarnem cepljenju dojenčkov mlajših od 6 mesecev s 3 odmerki, razen za serotip 5.
The open label period of the study provided an assessment of the ability of abatacept to maintain efficacy for subjects originally randomized to abatacept and the efficacy response of those subjects who were switched to abatacept following treatment with infliximab.
Na osnovi odprtega obdobja študije so ocenili, da abatacept ohrani učinkovitost pri osebah, ki so bile izvorno randomizirane na abatacept, in učinkovitost odziva pri tistih osebah, pri katerih je bilo zdravljenje z abataceptom uvedeno po predhodnem zdravljenju z infliksimabom.
The open, prospective, single-arm clinical trial enrolled 23 liver transplant recipients, who had been receiving intravenous hepatitis B immunoglobulin prophylaxis and subsequently switched to subcutaneous Zutectra.
Odprto, prospektivno klinično preskušanje z eno skupino je vključevalo 23 prejemnikov presajenih jeter, ki so predhodno prejemali intravensko imunoglobulinsko profilakso proti hepatitisu tipa B in so naknadno prešli na subkutano zdravilo Zutectra.
The opposite side is marked with the company symbol.
Na drugi strani tablete je znak podjetja.
The optimal duration of treatment has not been established.
Optimalno trajanje zdravljenja ni bilo ugotovljeno.
The optimal duration of treatment is unknown.
Optimalni čas zdravljenja ni znan.
The optimal therapeutic management of patients with YMDD mutant HBV has not yet been established (see section 4.4).
Optimalno zdravljenje bolnikov z YMDD mutantom HBV še ni ugotovljeno (glejte poglavje 4.4).
The optimal treatment duration is unknown.
Optimalno trajanje zdravljenja ni znano.
The optimum dosage is based upon the degree and chronicity of the anaemia and the desired duration of the effect. (See Table A Pharmacokinetic Parameters)
Optimalni odmerki so odvisni od stopnje in kroničnosti anemije ter od želenega trajanja učinka. (Glej Preglednico A Farmakokinetični parametri.)
The OPTISON vial must be inverted and gently rotated for approximately three minutes to completely resuspend the microspheres.
Vialo kontrastnega sredstva OPTISON morate obrniti navzdol in nežno vrteti približno tri minute, da se mikrosfere popolnoma resuspendirajo.
The oral absorption of enoxaparin is unlikely.
Peroralna absorpcija enoksaparina ni verjetna.
The oral administration of difloxacin at up to 5 times the recommended dose rate for 30 days did not result in any adverse reactions.
Peroralno dajanje petkrat večjih odmerkov v obdobju 30 dni ni povzročilo nastanka neželenih učinkov.
The oral bioavailability may be increased by 75 % after a single dose and 37 % at steady state compared to the reference capsule formulation when the pellets are taken without the Hydroxypropylmethylcellulose (HPMC) capsule shell.
Pri peroralnem jemanju se lahko biološka uporabnost po enkratnem odmerku poveča za 75%, v stanju dinamičnega ravnovesja pa za 37%, v primerjavi z referenčno kapsulo, ko jemljemo pelete brez ovoja iz hidroksipropilmetilceluloze (HPMC).
The oral bioavailability of Envarsus was decreased when the product was administered after a meal; the extent of absorption was decreased by 55% and the maximum plasma concentration was decreased by 22% when taken directly after a high-fat meal.
Peroralna biološka razpoložljivost zdravila Envarsus se je pri dajanju zdravila po obroku zmanjšala; absorpcije se je zmanjšala za 55 % in največja koncentracija v plazmi se je zmanjšala za 22 % po uporabi neposredno po obroku z visoko vsebnostjo maščobe.
The oral bioavailability of hydroxycarbamide is almost complete as assessed in indications other than Sickle Cell Syndrome.
Oralna biorazpoložljivost hidroksikarbamida je skoraj popolna, kot je bilo ugotovljeno za druge indikacije kot srpasto celični sindrom.
The oral bioavailability of tenofovir from tenofovir disoproxil fumarate in fasted patients was approximately 25%.
Peroralna biološka razpoložljivost tenofovirja iz dizoproksiltenofovirijevega fumarata je bila približno 25% pri teščih bolnikih.
The oral bioavailability of tenofovir from tenofovir disoproxil fumarate in fasted patients was approximately 25%.
Peroralna biološka uporabnost tenofovirja iz dizoproksiltenofovirijevega fumarata pri teščih bolnikih je bila približno 25 %.
The oral bioavailability of tenofovir from tenofovir disoproxil fumarate tablets in fasted patients was approximately 25%.
Peroralna biološka uporabnost tenofovirja iz tablet dizoproksiltenofovirijevega fumarata pri bolnikih na tešče je bila približno 25 %.
The oral contraceptive pill and alli
Peroralne kontracepcijske tablete in zdravilo alli
The oral contraceptive pill may be less effective if you get severe diarrhoea.
Če dobite hudo drisko, so peroralne kontracepcijske tablete lahko manj učinkovite.
The oral dispenser from the medicine pack.
peroralni odmernik, priložen v pakiranju
The oral dosing syringe and mixing cup should be cleaned immediately with warm water and dish soap after use.
Peroralno brizgo za odmerjanje in posodico za mešanje je treba takoj po uporabi očistiti s toplo vodo in tekočno za pomivanje posode.
The oral dosing syringe and mixing cup should be dry prior to use.
Peroralna brizga za odmerjanje in posodica za mešanje morata biti pred uporabo suhi.
The oral follow-up dose may be administered for up to a total of four doses at 24 hour intervals..
Peroralni nadaljevalni odmerek se lahko da največ štiri krat v 24-urnih intervalih.
The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to 4 days.
Peroralni nadaljevalni odmerek lahko dajemo enkrat na dan (v 24-urnih presledkih) največ do štiri dni.
The oral gel can be given 3 hours or earlier before a surgical operation.
Peroralni gel lahko dajemo 3 ure pred operativnim posegom ali prej.
The oral granules are used to make oral suspensions for children aged 4 weeks and older weighing at least 3 kg.
Peroralna zrnca se uporabijo za pripravo peroralne suspenzije za otroke, starejše od štirih tednov, ki tehtajo najmanj tri kilograme.
The oral LD50 in mouse is 1520 mg/kg.
Pri miših je peroralna vrednost LD50 1520 mg/kg.
The oral median lethal dose (LD50) of tolvaptan in rats and dogs is >2000 mg/kg.
Peroralni mediani smrtni odmerek (LD50) tolvaptana pri podganah in psih je > 2000 mg/kg.
The oral paste is available in the following pack sizes:
Pakiranja peroralne paste:
The oral paste is available in the following pack sizes:
Peroralna pasta je na voljo v naslednjih pakiranjih:
The oral powder contains:
Peroralni prašek vsebuje:
The oral powder is for use in individual pigs on farms where only a small number of pigs are to receive the treatment.
Za zdravljenje posameznih prašičev na farmah, kjer je zdravilo namenjeno le manjšemu številu prašičev.
The oral powder is mixed into pig feed by the pig owner and is used to treat individual pigs.
Peroralni prašek, ki se uporablja za zdravljenje posameznih prašičev, vmeša v prašičjo krmo lastnik prašiča sam.
The oral solution contains fructose and sucrose.
Peroralna raztopina vsebuje saharozo.
The oral solution contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).
Peroralna raztopina vsebuje metilparahidroksibenzoat in propilparahidroksibenzoat, ki lahko povzročita alergijske reakcije (lahko zapoznele).
The oral solution contains propylene glycol, which can cause adverse effects in high doses.
Peroralna raztopina vsebuje propilenglikol, ki lahko pri velikih odmerkih povzroči neželene učinke.
The oral solution has been shown to have greater bioavailability than the soft capsule formulation.
Pokazalo se je, da ima peroralna raztopina večjo biološko uporabnost kot mehke kapsule.
The oral solution is a clear, colorless to pale yellow solution.
Peroralna raztopina je bistra, brezbarvna do bledorumena raztopina.
The oral solution is clear to slightly opalescent yellowish, aqueous solution.
Peroralna raztopina je bistra do rahlo svetlikajoče rumenkasta vodna raztopina.
The oral solution is for patients who cannot take the tablets or capsules and is recommended for use in children (aged 12 years and under) because it allows for a more accurate dosing.
Peroralna raztopina je namenjena bolnikom, ki ne morejo jemati tablet ali kapsul, njena uporaba pa se priporoča pri otrocih (mlajših od 12 let), ker omogoča natančnejše odmerjanje.
The oral solution is packaged with an oral dosing syringe in a plastic tube container.
Peroralna raztopina je pakirana skupaj z brizgo za peroralno odmerjanje v plastičnem cevastem vsebniku.
The oral solution is prepared by dissolving the amount of powder of one vial in 50 ml of drinking water.
Peroralna raztopina se pripravi z raztapljanjem praška iz ene viale v 50 ml pitne vode.
The oral solution is the formulation to use in infants.
Farmacevtska oblika, ki je prilagojena za uporabo pri tej skupini, je peroralna raztopina.
The oral solution is the recommended option for the most accurate dosing in children based on body surface area.
Peroralna raztopina je priporočena možnost za najnatančnejše odmerjanje pri otrocih na podlagi telesne površine.
The oral solution or orodispersible tablets can be used in patients who have difficulty swallowing tablets.
Peroralna raztopina ali orodisperzibilne tablete se lahko uporabljajo pri bolnikih, ki težko pogoltnejo tableto.
The oral solution should be used by patients who weigh less than 33 kg, and by patients who cannot swallow the capsules.
Peroralno raztopino lahko uporabljajo le bolniki, ki tehtajo manj kot 33 kg, in bolniki, ki kapsul ne morejo pogoltniti.
The oral suspension can be kept at room temperature (not above 30oC) for up to 3 hours, prior to administration.
Peroralno suspenzijo se lahko hrani na sobni temperaturi (do 30 °C) do 3 ure pred uporabo.
The oral suspension can be kept at room temperature (not above 30°C) for up to 3 hours, prior to administration.
Peroralno suspenzijo se lahko hrani na sobni temperaturi (do 30 °C) do 3 ure pred uporabo.
The oral suspension must be shaken well before use.
Pred uporabo je treba peroralno suspenzijo dobro pretresti.
The oral suspension should be given by direct oral administration as shown below:
Dajemo direktno peroralno kot je prikazano na slikah spodaj:
The oral suspension should be prepared by the pharmacist using commercially available oseltamivir powder for oral suspension.
Peroralno suspenzijo mora pripraviti farmacevt z uporabo komercialno razpoložljivega praška za peroralno suspenzijo, ki vsebuje oseltamivir.
The oral suspension should be taken without food on an empty stomach in adults, but in younger patients it should be taken with food in order to hide the taste and help them stick to treatment.
Odrasli naj peroralno suspenzijo jemljejo brez hrane in na tešče, mlajši bolniki pa naj jo vzamejo s hrano, da se prikrije okus in jim pomaga, da se držijo zdravljenja.
The oral syringe cap should be removed before use to avoid risk of choking.
Pred uporabo z brizge za peroralno dajanje odstranite pokrovček, da preprečite nevarnost zadušitve.
The oral syringe should be cleaned immediately with hot water and dish soap after use.
Peroralno brizgo je treba takoj po uporabi očistiti z vročo vodo in milom za posodo.
The oral syringe should be emptied slowly to allow swallowing; rapid squirting of the medicine may cause choking.
Brizgo za peroralno dajanje je treba izprazniti počasi, da se omogoči požiranje; hitro brizganje zdravila lahko povzroči davljenje.
The oral syringes are graduated in 0.01 ml, 0.1 ml and 0.2 ml steps respectively.
Brizge za peroralno dajanje so graduirane v stopnjah po 0,01 ml, 0,1 ml in 0,2 ml.
The orally applied 13C-urea is metabolised to carbon dioxide and ammonia or is integrated into the body’s own urea cycle.
Zaužita 13C-sečnina se presnovi v ogljikov dioksid in amonijak ali se vključi v cikel sečnine v telesu.
The orange cap on a Repatha pre-filled pen contains a needle cover (located inside the cap) that is composed of dry natural rubber, which is made from latex.
V notranjosti oranžnega pokrovčka na napolnjenem injekcijskem peresniku je pokrovček igle; narejen je iz suhe naravne gume, ki je izdelana iz lateksa.
The orange-banana flavoured chewable tablet is oval-shaped, pale orange coloured, scored on both sides with the Merck logo and "477" on one side and without inscription on the other side.
Bledo oranžna, ovalna žvečljiva tableta, z okusom po pomaranči in banani, z razdelilno zarezo na obeh straneh, označena z logotipom Merck in oznako "477" na eni strani in brez napisa na drugi strani.
The orange-banana flavoured chewable tablet is round and pale yellow, marked with the Merck logo on one side and 473 on the other side.
Žvečljiva tableta z okusom po pomaranči in banani je okrogla in bledo rumene barve, označena z logotipom Merck na eni in oznako 473 na drugi strani.
The organic cation transporter (OCT)-related drug-drug interaction potential between methylnaltrexone bromide and an OCT inhibitor was studied in 18 healthy subjects by comparing the single-dose pharmacokinetic profiles of methylnaltrexone bromide before and after multiple 400 mg doses of cimetidine.
Pri 18 zdravih preiskovancih so proučevali možnost medsebojnega delovanja med zdraviloma, povezanega s prenašalcem organskih kationov (OCT), med metilnaltreksonijevim bromidom in zaviralcem OCT, tako da so primerjali farmakokinetični profil enkratnega odmerka metilnaltreksonijevega bromida pred več zaporednimi 400-miligramskimi odmerki cimetidina in po njih.
The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomised, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with ≤1 antidiabetic oral agent (88% of participants).
Študija ORIGIN (Outcome Reduction with Initial Glargine INtervention) je bila multircentrična, randomizirana študija s faktorskim načrtom 2 x 2, v katero je bilo vključenih 12.537 sodelujočih z velikim kardiovaskularnim (KV) tveganjem in okvarjeno glukozo na tešče (OGT) ali okvarjeno toleranco za glukozo (OTG) (12 % sodelujočih), ali s sladkorno boleznijo tipa 2, zdravljeno z ≤ 1 peroralnim antidiabetikom (88 % sodelujočih).
The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomized, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with ≤1 antidiabetic oral agent (88% of participants).
Študija ORIGIN (izboljšanje izida z začetnim dajanjem glargina) je bila multicentrična, randomizirana študija s faktorskim načrtom, opravljena na 12.537 preiskovancih z velikim srčno-žilnim (SŽ) tveganjem z moteno glukozo na tešče (IFG) ali moteno glukozno toleranco (IGT) (12 % preiskovancev) ali diabetesom tipa 2, zdravljenim z ≤1 peroralnim antidiabetikom (88 % preiskovancev).
The original analysis for cumulative genotypic resistance at week 104 and 208 was based on the ITT population and included all patients who continued treatment until 4 years, regardless of HBV DNA levels.
Prvotna analiza kumulativnih deležev genotipske rezistence po 104 oziroma 208 tednih je temeljila na podatkih populacije ITT (populacije z namenom zdravljenja) in je vključevala podatke vseh bolnikov, ki so nadaljevali zdravljenje skupno 4 leta, ne glede na koncentracijo HBV DNA.
The orodispersible tablet is moisture sensitive so should be taken immediately after opening the blister.
Orodisperzibilna tableta je občutljiva na vlago, zato jo mora bolnik vzeti takoj po odprtju pretisnega omota.
The orodispersible tablets are taken by being placed on the tongue, where they disintegrate in the saliva, or by mixing them in water before swallowing.
Orodisperzibilne tablete se zaužije tako, da se položijo na jezik, kjer jih slina raztopi, ali tako, da se pred zaužitjem zmešajo z vodo.
The orodispersible tablets are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
Orodisperzibilne tablete se zaužije tako, da se jih položi na jezik, kjer jih slina hitro raztopi, ali tako, da se pred zaužitjem zmešajo z vodo.
The orodispersible tablets should not be handled with wet hands as the tablets may break up.
Orodisperzibilnih tablet naj se ne prijema z vlažnimi rokami, da se ne zlomijo.
The orodispersible tablets, which can be used as an alternative to the tablets, are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
Orodisperzibilne tablete, ki se lahko uporabijo kot alternativa tabletam, se zaužijejo tako, da se jih položi na jezik, kjer jih slina hitro raztopi, ali tako, da se jih pred zaužitjem zmeša z vodo.
The orodispersible tablets, which can be used as an alternative to the tablets, are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
Orodisperzibilne tablete, ki se lahko uporabijo kot alternativa tabletam, se zaužijejo tako, da se položijo na jezik, kjer jih slina hitro raztopi, ali tako, da se pred zaužitjem zmešajo z vodo.
The ORR and DOR were assessed using criteria adopted from the Third International Workshop of Waldenström’s macroglobulinaemia.
ORR in čas trajanja odgovora (DOR- duration of response) so ocenili z uporabo kriterijev tretje mednarodne delavnice o Waldenstromovi makroglobulinemiji.
The ORR in the Cyramza plus paclitaxel arm was 27.9% and in the placebo plus paclitaxel arm was 16.1%.
Objektivna stopnja odziva v skupini z zdravilom Cyramza in paklitakselom je znašala 27,9 %, v skupini s placebom in paklitakselom pa 16,1 %.
The ORR was 36 % (CI95 % 21 % – 51 %; CR 3 %, PR 33 %) with a median TTP for responding patients of 9.6 months (range 4.5 to 26.8 months).
Celokupen odgovor je znašal 36 % (95-% interval zaupanja 21–51 %; popoln odgovor 3 %, delni odgovor 33 %); mediana časa do napredovanja bolezni je za odzivne bolnike znašala 9,6 meseca (razpon 4,5 do 26,8 meseca).
The ORR was 57 % (95% Confidence interval (CI); 41% – 73%; CR 14 %, PR 43%) with a projected median TTP for responding patients of 19.4 months (range 5.3 to 38.9 months).
Celokupen odgovor je znašal 57 % (95-% interval zaupanja 41 %–73 %; popoln odgovor 14 %, delni odgovor 43 %), mediana časa do napredovanja bolezni je bila pri odzivnih bolnikih 19,4 meseca (razpon 5,3 do 38,9 meseca).
The ORR was 57% (95% Confidence interval (CI); 41% – 73%; CR 14%, PR 43%) with a projected median TTP for responding patients of 19.4 months (range 5.3 to 38.9 months).
Celokupen odgovor je znašal 57 % (95-% interval zaupanja 41 %–73 %; popoln odgovor 14 %, delni odgovor 43 %), mediana časa do napredovanja bolezni je bila pri odzivnih bolnikih 19,4 meseca (razpon 5,3 do 38,9 meseca).
The OS data were not mature at the time of the PFS analysis.
V času analize preživetja brez napredovanja bolezni podatki o celokupnem preživetju še niso bili zreli.
The OS HRs for pembrolizumab 2 mg/kg every 3 weeks vs. chemotherapy were
RO za celokupno preživetje za pembrolizumab 2 mg/kg na 3 tedne v primerjavi s kemoterapijo sta bili
The OS HRs for pooled pembrolizumab vs. chemotherapy were 0.82 (95% CI: 0.55, 1.23) for PD-L1 positive patients and 0.77 (95% CI: 0.43, 1.37) for PD-L1 negative patients.
RO za celokupno preživetje za pembrolizumab kumulativno v primerjavi s kemoterapijo sta bili med PD-L1 pozitivnimi bolniki 0,82 (95 % IZ: 0,55; 1,23), med PD-L1 negativnimi pa 0,77 (95 % IZ: 0,43; 1,37).
The OS HRs for pooled pembrolizumab vs. chemotherapy were 0.83 (95% CI: 0.60, 1.15) for BRAF wild type and 0.82 (95% CI: 0.47, 1.43) for BRAF mutant with prior BRAF treatment.
RO za celokupno preživetje za pembrolizumab kumulativno v primerjavi s kemoterapijo sta bili 0,83 (95 % IZ: 0,60; 1,15) za divji tip BRAF in 0,82 (95 % IZ: 0,47; 1,43) za mutacijo BRAF s predhodnim zdravljenjem BRAF.
The OS HRs for pooled pembrolizumab vs. ipilimumab were 0.61 (95% CI: 0.46, 0.82) for BRAF wild type, 0.69 (95% CI: 0.33, 1.45) for BRAF mutant without prior BRAF
RO za celokupno preživetje za pembrolizumab kumulativno v primerjavi z ipilimumabom so bila 0,61 (95 % IZ: 0,46; 0,82) za divji tip BRAF,
The OS rate by specific timepoint is displayed graphically in Figure 4.
Delež celokupnega preživetja v specifični časovni točki je grafično prikazan na sliki 4.